| 4.7 -0.02 (-0.42%) | 10-07 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 7.71 | 1-year : | 9.34 |
| Resists | First : | 6.6 | Second : | 8 |
| Pivot price | 5.69  |
|||
| Supports | First : | 4.34 | Second : | 3.61 |
| MAs | MA(5) : | 4.63 |
MA(20) : | 5.98 |
| MA(100) : | 5.12 |
MA(250) : | 8.32 |
|
| MACD | MACD : | -0.5 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 10.5 |
D(3) : | 7.3 |
| RSI | RSI(14): 34.9 |
|||
| 52-week | High : | 41.79 | Low : | 3.25 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ QNRX ] has closed above bottom band by 26.5%. Bollinger Bands are 137.9% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 6 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 4.84 - 4.86 | 4.86 - 4.88 |
| Low: | 4.56 - 4.59 | 4.59 - 4.61 |
| Close: | 4.65 - 4.7 | 4.7 - 4.74 |
Quoin Pharmaceuticals, Ltd. operates as a specialized pharmaceutical firm, concentrating its efforts on devising therapeutic solutions for rare and orphan medical conditions. Its flagship offering, QRX003, is a topical lotion specifically formulated to address Netherton Syndrome. Furthermore, the company is advancing QRX004 for the management of dystrophic epidermolysis bullosa, alongside QRX006, a prospective therapy for an additional rare dermatological ailment. The organization maintains its operational base in Ashburn, Virginia.
Wed, 07 Oct 2026
Two parties report a passive stake in Quoin Pharmaceuticals (QNRX), covering 211,538 depositary shares. - Stock Titan
Mon, 28 Sep 2026
Weekly Recap: Interim Phase 2/3 QRX003 success and Lake Street $20.00 target - TradingView
Mon, 28 Sep 2026
Quoin Pharmaceuticals Ltd. SEC Filing (Sep 28, 2026) - Stock Titan
Thu, 24 Sep 2026
Quoin Pharmaceuticals Ltd. (QNRX) Posts Positive Interim QRX003 Data, Announces Up To $50M Financing - TradingView
Tue, 22 Sep 2026
Quoin Pharmaceuticals Announces FDA Fast Track Designation for QRX003 for the Treatment of Peeling Skin Syndrome - Yahoo! Finance Canada
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 2 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 8.7 (%) |
| Held by Institutions | 66.3 (%) |
| Shares Short | 111 (K) |
| Shares Short P.Month | 156 (K) |
| EPS | -5.68 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 8.76 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -114.6 % |
| Return on Equity (ttm) | -575.8 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -9.48 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -15 (M) |
| Levered Free Cash Flow | -8 (M) |
| PE Ratio | -0.83 |
| PEG Ratio | 0 |
| Price to Book value | 0.53 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.62 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|